HIV, Globalization and Topology: Of Prepositions and Propositions

Theory, Culture & Society

Volumn 29, Issue 5, 2012, Pages 93-115

  Michael, Mike ^a   Rosengarten, Marsha ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

globalization; HIV; prepositions; propositions; topology

Indexed keywords

EID: 84867073512     PISSN: 02632764     EISSN: 14603616     Source Type: Journal    
DOI: 10.1177/0263276412443567     Document Type: Article

References (54)

1. Ashmore, M. (1989) The Reflexive Thesis: Writing Sociology of Scientific Knowledge. Chicago: University of Chicago Press.
2. AVAC (AIDS Vaccine Advocacy Coalition) (2008) Anticipating the Results of PrEP Trials. Report from AVAC Anticipating and Understanding Results Series, URL (consulted 2 June 2011): http://www.avac.org/ht/a/GetDocumentAction/i/3120.
3. Biehl, J. (2007) Will to Live: AIDS Therapies and the Politics of Survival. Princeton, NJ: Princeton University Press.
4. Blok A. (2010) Topologies of Climate Change: Actor-network Theory, Relational-scalar Analytics, and Carbon-market Overflows, Environment and Planning D: Society and Space 28(5): 896–912.
5. Bowker, G.C. and S.L. Star (1999) Sorting Things Out: Classification and its Consequences. Cambridge, MA: MIT Press.
6. Cooper M. (2011) Trial by Accident: Tort Law, Industrial Risks and the History of Medical Experiment, Journal of Cultural Economy 4(1): 81–96.
7. Craddock, S. (2004) ‘AIDS and Ethics: Clinical Trials, Pharmaceuticals, and Global Scientific Practice’, pp. 240–51 in E. Kalipeni, S. Craddock, J.R. Oppong and J. Ghosh (eds) HIV and AIDS in Africa: Beyond Epidemiology. Malden, MA: Blackwell.
8. DeLanda M. (2002) Intensive Science and Virtual Philosophy. London: Continuum.
9. Deleuze, G. and F. Guattari (1988) A Thousand Plateaus: Capitalism and Schizophrenia. London: Athlone Press.
10. Fassin, D. (2007) When Bodies Remember: Experiences and Politics of AIDS in South Africa. Berkeley: University of California Press.
11. GCM (Global Campaign for Microbicides) (2008a) Research Rashomon Lessons from the Cameroon Pre-exposure Prophylaxis Trial Site. Report, URL (consulted 1 June 2011): http://www.global-campaign.org/clientfiles/Cameroon.pdf.
12. GCM (Global Campaign for Microbicides) (2008b) Preventing Prevention Trial Failures: A Case Study and Lessons for Future Trials from the 2004 Tenofovir Trial in Cambodia. Report, URL (consulted 1 June 2011): http://www.global-campaign.org/clientfiles/Cambodia.pdf.
13. Gilead Sciences Inc. (2011) Expanding Antiretroviral Treatment Coverage in the Developing World. Report, URL (consulted 1 June 2011): http://www.gilead.com/pdf/GAPHistory.pdf.
14. Grant R.M. et al. (2005) AIDS: Promote HIV Chemoprophylaxis Research, Don't Prevent It, Science 30(September): 2170–1.
15. Halewood M. M. Michael. (2008) Being a Sociologist and Becoming a Whiteheadian: Concrescing Methodological Tactics, Theory, Culture & Society 25(4): 31–56.
16. Hirsch, J.S., H. Wardlow, D.J. Smith, H.M. Phinney, S. Parikh and C.A. Nathanson (2009) The Secret: Love, Marriage, and HIV. Nashville, TN: Vanderbilt University Press.
17. Human Rights Watch (2004) Thailand – Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights, June, vol. 16, no. 8 (C). URL (consulted 2 June 2011): http://www.hrw.org/en/reports/2004/07/07/not-enough-graves-0.
18. Jintarkanon S. et al. (2005) Unethical Clinical Trials in Thailand: A Community Response, Lancet 365: 1617–18.
19. Kalipeni, E., S. Craddock and J. Ghosh (2004) ‘Mapping the AIDS Pandemic in Eastern and Southern Africa: The Geographical Progression of HIV in Eastern and Southern Africa’, pp. 58–69 in E. Kalipeni, S. Craddock, J.R. Oppong and J. Ghosh (eds) HIV and AIDS in Africa: Beyond Epidemiology. Malden, MA: Blackwell.
20. Kalipeni, E., S. Craddock, J. Oppong and J. Ghosh (eds) (2004) HIV and AIDS in Africa: Beyond Epidemiology. Malden, MA: Blackwell.
21. Kippax S. (2008) Understanding and Integrating the Structural and Biomedical Determinants of HIV Infection: A Way Forward for Prevention, Current Opinion in HIV and AIDS 3: 489–494.
22. Kippax, S. (2010) ‘Reframing the Social Dimensions of HIV: Treatment as Prevention’, Keynote address at Reframing the Social Dimensions of HIV in a Biomedicalised Epidemic: The Case of Treatment as Prevention International Conference sponsored by the Overseas Development Institute, San Francisco AIDS Foundation and Goldsmiths, University of London, 5 March.
23. Lash, S. and C. Lury (2007) Global Culture Industry: The Mediation of Things. Cambridge: Polity.
24. Latour, B. (1999) Pandora's Hope: Essays on the Reality of Science Studies. Cambridge, MA: Harvard University Press.
25. Latour, B. (2005) Reassembling the Social: An Introduction to Actor-Network Theory. Oxford: Oxford University Press.
26. MacQueen K.M. Namey E. Chilongozi D.A. Mtweve S.P. Mlingo M. Morar N. et al. (2007) Community Perspectives on Care Options for HIV Prevention Trial Participants, AIDS Care 19(4): 554–60.
27. Michael M. (2004) Roadkill: Between Humans, Nonhuman Animals, and Technologies, Society & Animals 12(4): 277–298.
28. Michael, M. (2009) ‘Temporality, Topology and Sociology’, pp. 94–5 in G. Ascione, C. Massip and J. Perello (eds) Cultures of Change: Social Atoms and Electronic Lives. Barcelona: Actar and Arts Santa Monica.
29. Michael, M. and M. Rosengarten (forthcoming) ‘Quantitative Objects and Qualitative Things: Ethics and HIV Biomedical Prevention’, in P. Harvey, E. Casella and G. Evans (eds) Objects and Materials: A Routledge Companion. London: Routledge.
30. Mills E. et al. (2005) Media Reporting of Tenofovir Trials in Cambodia and Cameroon, BMC International Health and Human Rights 5(6): 1–7.
31. Mol A. J. Law. (1994) Regions, Networks and Fluids: Anaemia and Social Topology, Social Studies of Science 24(4): 641–71.
32. Padian N.S. Buvé A. Balkus J. Serwadda D. Cates W. (2008) Biomedical Interventions to Prevent HIV Infection: Evidence, Challenges, and Way Forward, Lancet 372(9638): 585–99.
33. Padian N.S. McCoy S.I. Balkus J.E. Wasserheit J.N. (2010) Weighing the Gold in the Gold Standard: Challenges in HIV Prevention Research, AIDS 24(15): 621–35.
34. Petryna A. (2005) Ethical Variability: Drug Development and Globalizing Clinical Trials, American Ethnologist 32: 183–97.
35. Piot P. Bartos M. Larson H. Zewdie D. Mane P. (2008) Coming to Terms with Complexity: A Call to Action for HIV Prevention, Lancet 372(9641): 845–59.
36. Power, M. (1999) The Audit Society. Oxford: Oxford University Press.
37. Rosengarten M. M. Michael. (2009) Rethinking the Bioethical Enactment of Drugged Bodies: On the Paradoxes of Using Anti-HIV Drug Technology for Prevention, Science as Culture 18: 183–99.
38. Serres, M. (1982a) Hermes: Literature, Science, Philosophy. Baltimore, MD: Johns Hopkins University Press.
39. Serres, M. (1982b) The Parasite. Baltimore, MD: Johns Hopkins University Press.
40. Serres M. (1995) Angels: A Modern Myth. Paris: Flammarion.
41. Serres, M. and B. Latour (1995) Conversations on Science, Culture and Time. Ann Arbor: Michigan University Press.
42. Stephenson J. J. Imrie. (1998) Why Do We Need Randomised Controlled Trials to Assess Behavioural Interventions?, British Medical Journal 316(7131): 611–13.
43. Sundar Rajan K. (2007) Experimental Values: Indian Clinical Trials and Surplus Health, New Left Review 45: 67–88.
44. Szerszynski B. (2012) The Force of Experiment, Theory Culture & Society 29(4/5).
45. The Thai AIDS Treatment Action Group TTATAG (2004) Letter, 8 December, URL (consulted 5 May 2011): http://www.aidsinfonyc.org/tag/activism/thaiTenofovir.html.
46. UNAIDS (2006a) Report on the Global AIDS Epidemic: Executive Summary. UNAIDS 10th anniversary special edition. URL (consulted March 2012): http://data.unaids.org/pub/GlobalReport/2006/2006_gr-executivesummary_en.pdf.
47. UNAIDS (2006b) ‘Creating Effective Partnerships for HIV Prevention Trials: Report of the UNAIDS Consultation, Geneva, 20–21 June 2005’. URL (consulted 2 June 2011): http://journals.lww.com/aidsonline/fulltext/2006/04040/creating_effective_partnerships_for_hiv_prevention.33.aspx.
48. UNAIDS and AVAC (2007) Good Participatory Practice Guidelines for Biomedical HIV Prevention Trial. Report produced by Joint United Nations Programme on HIV/AIDS (UNAIDS) and AVAC. URL (consulted 2 June 2011): http://www.avac.org/ht/a/GetDocumentAction/i/2824.
49. UNAIDS/WHO (2007) Ethical Considerations in Biomedical Prevention Trials: UNAIDS/WHO Guidance Document. URL (consulted 2 June 2011): http://data.unaids.org/pub/Report/2007/jc1399_ethical_considerations_en.pdf.
50. Vernazza P. (2009) Editorial: The Debate Continues: Does “Undetectable” Mean “Uninfectious”?’, HIV Therapy 3(2): 113–16.
51. Whitehead, A.N. (1978 [1929]) Process and Reality: An Essay in Cosmology. New York: The Free Press.
52. Will, C. and T. Moreira (eds) (2010) Medical Proofs and Social Experiments: Clinical Trials in Shifting Contexts. Farnham, Surrey: Ashgate.
53. Woolgar, S. (ed.) (1988) Knowledge and Reflexivity: New Frontiers in the Sociology of Knowledge. London: Sage.
54. Wynne, B.E. (1989) ‘Frameworks of Rationality in Risk Management: Towards the Testing of Naive Sociology’, pp. 33–47 in J. Brown (ed.) Environmental Threats. London: Belhaven Press.